Home
RNXT
RNXT News

Latest RenovoRx Inc. (RNXT) News on October 9, 2025

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

GlobeNewswire

a month ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 06/27/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 06/25/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/24/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/23/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/20/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/18/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/17/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/16/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/13/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/12/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/11/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/10/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/09/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/06/2025

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

Insider Monkey

4 months ago

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/05/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/04/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/03/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/02/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 05/30/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 05/29/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 05/28/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 05/27/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/23/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/22/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/21/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/20/2025

Thomson Reuters StreetEvents

5 months ago

Q1 2025 RenovoRx Inc Earnings Call

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/16/2025

GuruFocus.com

5 months ago

RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

Zacks

5 months ago

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

Business Wire

5 months ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/15/2025

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

Business Wire

5 months ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/14/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/13/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/09/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/08/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/07/2025

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

Business Wire

5 months ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/06/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/05/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/02/2025

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Business Wire

5 months ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/01/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 04/30/2025

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

Business Wire

5 months ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 04/29/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 04/28/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 04/25/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/24/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/23/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/22/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/21/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/18/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/17/2025

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Business Wire

6 months ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/16/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/15/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/14/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/11/2025

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Business Wire

6 months ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Business Wire

6 months ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Business Wire

6 months ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Business Wire

6 months ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Business Wire

7 months ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Business Wire

7 months ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Business Wire

7 months ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Business Wire

8 months ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Business Wire

8 months ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement

GuruFocus.com

8 months ago

RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Business Wire

8 months ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Business Wire

8 months ago

RenovoRx Announces Proposed Public Offering

ASCO GI: RenovoRX’s TAMP system reduces side effects in pancreatic cancer

Clinical Trials Arena

8 months ago

ASCO GI: RenovoRX’s TAMP system reduces side effects in pancreatic cancer

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Business Wire

8 months ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Analysts Expect Breakeven For RenovoRx, Inc. (NASDAQ:RNXT) Before Long

Simply Wall St.

9 months ago

Analysts Expect Breakeven For RenovoRx, Inc. (NASDAQ:RNXT) Before Long

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Business Wire

9 months ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Business Wire

9 months ago

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

GlobeNewswire

10 months ago

RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET

GlobeNewswire

10 months ago

RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET

RenovoRx begins commercialisation of RenovoCath device

Medical Device Network

10 months ago

RenovoRx begins commercialisation of RenovoCath device

RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System

GlobeNewswire

10 months ago

RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System

MT Newswires

a year ago

RenovoRx Says Northwell Health Cancer Institute Begins Enrolling Patients for Phase III Pancreatic Cancer Trial

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

GlobeNewswire

a year ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

GlobeNewswire

a year ago

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully

Simply Wall St.

a year ago

We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

GlobeNewswire

a year ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

GlobeNewswire

a year ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York

GlobeNewswire

a year ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York

RenovoRx continues drug-device combo Phase III trial in pancreatic cancer

Medical Device Network

a year ago

RenovoRx continues drug-device combo Phase III trial in pancreatic cancer

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

GlobeNewswire

a year ago

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®

GlobeNewswire

a year ago

RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

GlobeNewswire

a year ago

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial

GlobeNewswire

a year ago

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

GlobeNewswire

a year ago

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

RenovoRx CEO Issues Update Letter to Shareholders

Business Wire

a year ago

RenovoRx CEO Issues Update Letter to Shareholders

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

Business Wire

a year ago

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

Business Wire

a year ago

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

Business Wire

a year ago

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

Share on Social Networks: